Smart Insulin Pen in Pregnant Women with Type 1 Diabetes: An Encouraging Case Series

<b>Background:</b> The management of type 1 diabetes in pregnancy with new technologies is challenging. Sometimes the complexity of new-generation systems such as "continuous subcutaneous insulin infusion, CSII" and patient or provider preference do not allow their use, so women with type 1 diabetes in pregnancy continue to be treated with subcutaneous multiple-injection insulin therapy using pens. Smart insulin pens are new tools that allow for data collection on insulin dose and time of administration and have additional connectivity features. <b>Objective:</b> To retrospectively describe the use of a smart insulin pen coupled with rt-CGM (InPen^TM system) in three pregnancies complicated by type 1 diabetes. <b>Methods:</b> Participants used the InPen^TM system in pregnancy and consented to analysis of glycaemic data and pregnancy outcome. <b>Results:</b> An increase in pregnancy specific time-in-range glucose was observed in the three patients related to the duration of insulin action, insulin sensitivity factors, and a pre-set target glucose range for pregnancy. No diabetic ketoacidosis or severe hypoglycaemia occurred. <b>Conclusions:</b> We describe practical considerations in three pregnant patients with type 1 diabetes where the InPen^TM system was used with suggestive improvements in the time-in-range.